Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials

Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy.

(2017) R. Pettengell et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

(2010) Marinus H.J. van Oers et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

(2010) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study

(2010) Anna Johnston et al.   LEUKEMIA & LYMPHOMA

Patterns of survival of follicular lymphomas at a single institution through three decades

(2010) Annarita Conconi et al.   LEUKEMIA & LYMPHOMA

An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

(2010) Joshua A. Ray et al.   VALUE IN HEALTH

A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

(2009) R Marcus et al.   BRITISH JOURNAL OF CANCER

Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

(2009) Stefano Luminari et al.   CANCER

Japanese phase II study of90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

(2009) Kensei Tobinai et al.   CANCER SCIENCE

Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study

(2009) Howard Hochster et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'Adulte

(2009) Emmanuel Bachy et al.   JOURNAL OF CLINICAL ONCOLOGY

Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial

(2009) A. B. Delaloye et al.   JOURNAL OF NUCLEAR MEDICINE

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials

(2009) Liat Vidal et al.   JNCI-Journal of the National Cancer Institute

Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden

(2008) Frida Kasteng et al.   ACTA ONCOLOGICA

Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial

(2008) Mathias Witzens-Harig et al.   ANNALS OF HEMATOLOGY

Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century

(2008) Dianne Pulte   ARCHIVES OF INTERNAL MEDICINE

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

(2008) G. Salles et al.   BLOOD

Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma

(2008) L K Hicks et al.   BONE MARROW TRANSPLANTATION

Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma

(2008) S. A. Jacobs et al.   CLINICAL CANCER RESEARCH

Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study

(2008) Catherine Sebban et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

(2008) Eva Kimby et al.   LEUKEMIA & LYMPHOMA